Effectiveness of Licorice Extract Dietary Supplement on the Treatment of Postmenopausal Symptoms

Sponsor
F&C Licorice Ltd (Other)
Overall Status
Unknown status
CT.gov ID
NCT01170195
Collaborator
(none)
120
1
12
10

Study Details

Study Description

Brief Summary

The purpose of the proposed study is to test the effect of Licorice Root Extract- Licogen on postmenopausal symptoms in postmenopausal women. Specifically, the study will also test the effect of the licorice extract on vaginal dryness.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Calmera-Licorice Root Extract (Licogen)
Phase 1/Phase 2

Detailed Description

The estrogenic properties of glabridin, the major isoflavan in licorice root, were tested in view of the resemblance of its structure and lipophilicity to those of estradiol. The results indicate that glabridin is a phytoestrogen, binding to the human estrogen receptor and stimulating creatine kinase activity in rat uterus, epiphyseal cartilage, diaphyseal bone, aorta, and left ventricle of the heart. The stimulatory effects of 2.5-25 mg/animal glabridin were similar to those of 5 mg/animal estradiol. Chemical modification of glabridin showed that the position of the hydroxyl groups has a significant role in binding to the human estrogen receptor and in proliferation-inducing activity. Glabridin was found to be three to four times more active than 2-O-methylglabridin and 4-O-methylglabridin, and both derivatives were more active than 2*,4*- O-methylglabridin. The effect of increasing concentrations of glabridin on the growth of breast tumor cells was biphasic. Glabridin showed an estrogen receptor-dependent, growth-promoting effect at low concentrations (10 nM-10 mM) and estrogen receptor-independent antiproliferative activity at concentrations of

15 mM. This is the first study to indicate that isoflavans have estrogen-like activities. Glabridin and its derivatives exhibited varying degrees of estrogen receptor agonism in different tests and demonstrated growth-inhibitory actions on breast cancer cells.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effectiveness of Licorice Extract Dietary Supplement on the Treatment of Postmenopausal Symptoms
Study Start Date :
Sep 1, 2010
Anticipated Primary Completion Date :
Sep 1, 2011
Anticipated Study Completion Date :
Sep 1, 2011

Outcome Measures

Primary Outcome Measures

  1. A beneficial effect of the licorice extract on postmenopausal symptoms (vasomotor symptoms, and nocturnal episodes) in symptomatic postmenopausal women [20 weeks]

    This outcome will be measured by: a diary in which she should report daily. The reporting would be for 3 parameters: number of hot flushes per day, wakefull night episodes and nocturnal sweating measured by Greens Climateric Scale

  2. A beneficial effect of the licorice extract on vaginal complaints in symptomatic postmenopausal women [20 weeks]

    this objective will be measured by Pap Smear, Vaginal Ultra sound and vaginal PH

Eligibility Criteria

Criteria

Ages Eligible for Study:
45 Years to 60 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Women between the ages 45-60,

  2. Who are post-menopausal (proved by a laboratory test of FSH > 30 International units),

  3. Patients who report having post-menopausal symptoms, who report having, at least 5-7 hot flushes per day, as well as wakeful night episodes and nocturnal sweating (measured by Greenscale or Cooperman Index).

Exclusion Criteria:
  1. Female patients who are outside the age boundaries of 45-60,

  2. Have FSH <30

  3. Patients who presently have cancer of any kind,

  4. Patients that are on any other treatment for relieving post-menopausal symptoms

  5. Patients who have contraindication to Licorice.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Rabin Medical Center Petah Tikva Israel

Sponsors and Collaborators

  • F&C Licorice Ltd

Investigators

  • Principal Investigator: Boris Kaplan, MD, Rabin Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT01170195
Other Study ID Numbers:
  • 5459
First Posted:
Jul 27, 2010
Last Update Posted:
Jul 27, 2010
Last Verified:
Jul 1, 2010
Keywords provided by , ,

Study Results

No Results Posted as of Jul 27, 2010